Erector Spinae Plane Block vs Trigger Point Injection for Back Pain

This trial explores two types of injections to help people with chronic mid-back pain. Researchers aim to determine which treatment—the erector spinae plane (ESP) block or trigger point injection (TPI)—provides better relief, improves physical function, boosts emotional well-being, and achieves higher patient satisfaction. Participants will be randomly assigned to receive one of these treatments and monitored for 12 weeks through questionnaires and pain assessments. Ideal candidates for this trial are adults who have experienced chronic mid-back pain for at least three months and have intense pain with specific patterns in their back muscles. As a Phase 4 trial, this study involves treatments already FDA-approved and proven effective, aiming to understand how they can benefit more patients.

Research has shown that both the Erector Spinae Plane (ESP) block and Trigger Point Injection (TPI) are generally safe for managing pain.

The ESP block, a type of regional anesthesia, numbs a specific area of the body. Studies have found it to be well-tolerated, with few complications. However, most safety information comes from individual case reports, so detailed data remains limited.

Trigger Point Injections also have a strong safety record. Research indicates that using anesthetics like bupivacaine without steroids results in minimal complications. Common side effects are usually mild, such as temporary discomfort or numbness at the injection site.

Researchers are excited about these treatments for back pain because they offer innovative approaches to pain management. The Erector Spinae Plane (ESP) Block uses ultrasound guidance to deliver anesthetic directly into the fascial plane around the erector spinae muscle, potentially providing more targeted pain relief with fewer side effects compared to systemic medications like opioids or NSAIDs. On the other hand, Trigger Point Injections (TPI) focus on relieving muscle knots by injecting anesthetic directly into the areas of muscle tension, offering a localized treatment option for muscle-related pain. Both methods aim to provide rapid pain relief through precise administration of bupivacaine, reducing reliance on oral pain medications and minimizing systemic exposure.

This trial will compare the effectiveness of the erector spinae plane (ESP) block and trigger point injections (TPI) for back pain. Research has shown that the ESP block can effectively reduce chronic pain. For instance, patients with long-term lower back pain reported about 90% improvement after receiving the ESP block. In another study, the ESP block significantly reduced pain compared to a placebo. Meanwhile, TPI relieves pain by injecting medicine directly into tight muscle areas. Although few studies directly compare these two treatments for chronic upper back pain, both have shown promise in reducing pain in various situations.⁴⁶⁷⁸⁹